Matinas BioPharma Holdings (MTNB) Other Accumulated Expenses (2018 - 2025)
Matinas BioPharma Holdings (MTNB) posted quarterly Other Accumulated Expenses of $120000.0 for Q3 2025, down 75.1% quarter-over-quarter from $482000.0 in Q2 2025.
Matinas BioPharma Holdings (MTNB) Other Accumulated Expenses (2018 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Other Accumulated Expenses for 7 consecutive years, with $120000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Accumulated Expenses changed N/A year-over-year to $120000.0; the TTM figure through Sep 2025 stood at $120000.0 (changed N/A YoY), while the FY2024 annual figure was $1.5 million, changed N/A from the prior year.
- Other Accumulated Expenses declined to $120000.0 in Q3 2025 per MTNB's latest filing, from $482000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.5 million in Q4 2024 and bottomed at $88000.0 in Q4 2022.
- Historically, Other Accumulated Expenses has averaged $634833.3 across 4 years, with a median of $592000.0 in 2022.
- Annual changes were most pronounced in 2021 — Other Accumulated Expenses soared 9299900.0% — and 2022, when it tumbled 90.21%.
- Matinas BioPharma Holdings' Other Accumulated Expenses stood at $899000.0 in 2021, then sank by 90.21% to $88000.0 in 2022, then surged by 1614.77% to $1.5 million in 2024, then sank by 92.05% to $120000.0 in 2025.
- Business Quant data shows MTNB's Other Accumulated Expenses at $120000.0 in Q3 2025, $482000.0 in Q2 2025, and $922000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 120,000.00 |
| Jun 30, 2025 | 482,000.00 |
| Mar 31, 2025 | 922,000.00 |
| Dec 31, 2024 | 1.51 Mn |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 194,000.00 |
| Jun 30, 2022 | 444,000.00 |
| Mar 31, 2022 | 702,000.00 |
| Dec 31, 2021 | 899,000.00 |
| Sep 30, 2021 | 1.23 Mn |
| Jun 30, 2021 | 840,000.00 |
| Mar 31, 2021 | 186,000.00 |
| Dec 31, 2020 | 643,000.00 |
| Mar 31, 2020 | 2.00 |
| Dec 31, 2019 | 13.00 |
| Jun 30, 2019 | 2,000.00 |
| Mar 31, 2019 | 2,000.00 |
| Dec 31, 2018 | 31,000.00 |